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Abstract 
 
Peptide-based materials are receiving significant attention for use within biomedicine due to 
their high chemical and functional versatility enabling tailoring of their structure to replicate 
the properties of host tissue and the extracellular matrix. This paper studies the design, 
synthesis and characterization of NSAID-peptide conjugates. Attachment of NSAIDs to a 
diphenylalanine-dilysine (FFKK-OH) peptide sequence generates supramolecular hydrogel 
forming molecules with antimicrobial and anti-inflammatory properties. NSAID-peptides 
demonstrate broad-spectrum antimicrobial activity against both Gram-positive and Gram-
negative bacteria implicated in a variety of antimicrobial resistant nosocomial infections 
including Staphylococcus aureus and Pseudomonas aeruginosa. Naproxen-peptides show 
particular promise, forming biocompatible nanofibrous viscoelastic hydrogels composed of β-
sheet secondary structures at low concentrations (0.4% w/v). Conjugation of the peptide motif 
FFKK-OH to naproxen increases selectivity for COX-2 enzyme, implicated in chronic wound 
scar-tissue formation. Our findings suggest that ultrashort NSAID-peptides have potential use 
as multifunctional materials for a range of biomedical applications. This includes as topical 
agents for treatment of chronic wounds, where a profile of persistent inflammation, pain and 
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the presence of infection has been proven to be detrimental to successful wound repair. This 
work may also serve as a template for the design of future medical device coatings with 
tailored antimicrobial and anti-inflammatory properties. 
 
Keywords: Nanostructure, hydrogel, infection, inflammation, chronic wound 
 
 
Introduction 
Antimicrobial resistance is becoming an increasingly menacing threat to society and is 
currently attributed to at least 700,000 deaths worldwide annually. A U.K Government review 
in 2014 concluded that without significant investment in new therapies this total would 
increase to more than 10 million deaths by 2050, a figure greater than predicted for cancer [1]. 
Hospital-acquired infections, especially those related to implantation of medical devices and 
skin wounds, are major contributors to this threat demonstrating an increased prevalence of 
microorganisms that display resistance to standardly employed antimicrobial therapies. These 
are responsible for increased patient morbidity and mortality, and significant economic cost 
due to extended hospital stay/sick days. Infections are particularly problematic among those 
with increased susceptibility and compromised immunity, for example the elderly and those 
with under-lying disease.  
 
Wound infections can be categorized into a variety of forms; most problematic being surgical 
site infections (SSIs), diabetic ulcers and major trauma, for example burns. SSIs are one of the 
most frequently reported hospital acquired infections accounting for 31% of nosocomial 
infections and are a reservoir for so-called hospital superbugs including Staphylococcus 
aureus and Pseudomonas aeruginosa [2]. SSIs are present in nearly 5% of patients who 
undergo a surgical procedure and over a third of postoperative deaths are related to SSIs [3]. It 
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is clear SSIs remain a significant burden to healthcare. Failure of antimicrobial therapy and/or 
unresolved healing can result in the development of a chronic wound. 
 
Chronic infected wounds are particularly problematic with a profile of exaggerated 
inflammation and resistant infection severely limiting wound healing [4]. They are 
responsible for multiple treatment failures and commonly require a minimum of eight weeks 
to fully resolve, due to increased microbial resistance to standard drug regimens and impaired 
healing. Nonhealing wounds costs the US healthcare system $3billion annually and affects 
over 2% of the population [5,6]. Acute and chronic wounds are resolved through similar 
biomolecular pathways, however chronic wounds commonly stall in the inflammatory phase 
partly due to the presence of pathogenic biofilm infection [7]. Implanted biomaterials are also 
associated with an exaggerated host immune response, termed the foreign body response. 
Sustained inflammation, present primarily within chronic wounds and biomaterial infections, 
has been proven to be detrimental to wound repair [8]. This has commonly been minimized 
and controlled using steroidal and non-steroidal anti-inflammatory drugs (NSAIDs), limiting 
the action of inflammatory mediators such as prostaglandins. Long-term systemic use of such 
drugs leads to undesirable side effects including adverse gastrointestinal, renal and 
cardiovascular risks. Debate still exists regarding the use of systemic NSAIDs to aid wound 
repair due to possible anti-proliferative effects demonstrated in animal studies and their 
possible contribution to increasing the severity of group A streptococcal infections [9][10]. 
Despite reservations with systemic NSAID use, localized sustained release systems are 
commonly employed and NSAID topical applications demonstrate benefit in the treatment of 
chronic wounds [11]. For example an ibuprofen foam formulation provides localized delivery, 
reduced pain, a moist environment and has been proven to be advantageous for the resolution 
of chronic venous leg ulcers [12]. 
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There has been increased interest in the therapeutic potential of antimicrobial peptides. 
Displaying multiple modes of intracellular and extracellular action, antimicrobial peptides 
demonstrate a reduced propensity for developing antimicrobial resistance and are a significant 
prospect for solving the current shortage of antimicrobials in pharmaceutical development 
[13]. Several research groups have studied their incorporation into synthetic hydrogel 
matrices for the prevention of biomaterial and wound infections with promising results thus 
far [14,15,16]. Hydrogels possessing inherent antimicrobial properties represent a significant 
benefit by reducing microbial contamination within the matrix and at the wound/implantation 
site [17]. Self-assembling biomimetic hydrogels, including peptide-based strategies, have 
received attention as biofunctional materials and drug delivery platforms due to their 
similarity to the extracellular tissue matrix. Peptide-based materials possess: increased 
chemical functionality and versatility; improved biocompatibility; increased water capacity; 
moisture vapor transmission and gaseous exchange; biodegradability and tailored 
immunogenicity. Hydrogels provide improved healing at wound sites by enabling rapid 
absorption of wound exudate and protection of newly formed skin. Researchers have begun to 
employ a strategy whereby peptides are optimized to obtain multi-functionality, both 
pharmacological (antimicrobial, anti-biofilm, anti-inflammatory, analgesia) and physical 
(self-assembly, hydrogelation), within a single molecule. Most recently our group developed 
an ultrashort cationic peptide motif with selective activity against resistant pathogens 
implicated in medical device related infections [18]. Ultrashort peptides are of particular 
interest to the pharmaceutical industry as they are generally more cost-effective to synthesize 
relative to their larger peptide/protein counterparts and therefore more realistic molecules for 
clinical translation.  
 
Self-assembling hydrogel systems based on drug molecules eliminates the necessity for a drug 
delivery vehicle, typically a synthetic polymer [19,20] and may be tailored to respond to 
  
5 
 
environmental and physiological stimuli, for example pH change or the presence of specific 
enzymes. Synthetic-based polymers demonstrate limited drug loading, are difficult to 
functionalize and acidic degradation products can induce an unwanted inflammatory response 
[21]. The presence of aromatic groups, such as those present within NSAIDs, facilitates 
assembly of NSAID-peptide conjugates where the NSAID moiety replaces more traditional 
aromatic groups found in self-assembling systems such as carboxybenzyl [22], 9-
fluorenylmethyloxycarbonyl (Fmoc) [23] and 2-naphthoyl (Nap) [24]. Work thus far has 
focused on NSAIDs clinically used as topical preparations for acute pain, for example 
ibuprofen and naproxen [25]. Recently a multifunctional approach has been successful in 
creating an anti-inflammatory and anti-HIV hydrogel using naproxen conjugated to reverse 
transcriptase inhibitors via a peptide linker [26]. The idea of a multifunctional antimicrobial 
and anti-inflammatory platform is adopted from nature where herb extracts curcumin 
(Curuma longa), dayflower (Commelina diffusa) and bark (Spathodea campanulata) have 
demonstrated benefit in wound healing [27,28] Building on previously investigated NSAID 
conjugated peptides and antimicrobial peptides we have developed novel self-assembling 
NSAID-peptides utilizing racemic (±)-ibuprofen (Ibu), indomethacin (Ind) and (S)-(+)-
naproxen (Npx) (Figure 1).    
 
 
This report examines the synthesis and characterization of NSAID conjugated ultrashort 
cationic self-assembled peptide hydrogels as potential antimicrobial and anti-inflammatory 
biomaterials. Incorporation of an NSAID into the ultrashort carboxylic acid terminated motif 
(FFKK-OH) was hypothesized to confer improved hydrogel strength and cyclooxygenase 
(COX) inhibitory properties to the molecule. The development of a NSAID conjugated 
hydrogelator may also serve as a carrier for other therapeutic agents since the arrest of the 
inflammatory response is one of the most important factors in successful application of 
biomaterials [29].  
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Materials and Methods 
Materials 
Wang resin preloaded with Fmoc-Lys(Boc) (mesh size 100-200, 0.65 mmol/g substitution), 
(2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexaﬂuorophosphate) (HBTU), 
diisopropyl ethylamine (DIEA), Fmoc and Boc protected amino acids were obtained from 
Novabiochem, Merck KGaA (Dramstadt, Germany). 37% hydrochloric acid (HCl), sodium 
hydroxide anhydrous pellets (≥99%), acetonitrile (HPLC grade, ≥99.93%), (±)-ibuprofen 
(≥98%), indomethacin (≥99%), (S)-(+)-naproxen (≥99%), deuterated dimethyl sulfoxide (d6-
DMSO), deuterium oxide (D2O), deuterium chloride (DCl), sodium deuteroxide (NaOD), 
trifluoracetic acid, triisopropylsilane, thioanisole and Whatman pH indicator paper (pH 1-14) 
were purchased from Sigma-Aldrich (Dorset, U.K.). NCTC Clone 929 (ATCC CCL 1) 
murine fibroblast subcutaneous connective tissue cells, S. epidermidis (ATCC 25984), S. 
aureus (ATCC 6584), P. aeruginosa (PAO1) and E. coli (ATCC 11303) supplied by LGC 
Standards (London, U.K). AlamarBlue® was obtained from AbD Serotec (Oxford, U.K.). 
Sterile Nunc™ 96-well microtiter plates supplied by VWR International (Leicestershire, 
U.K.). Fresh defibrinated equine erythrocytes were purchased from Laboratory Supplies and 
Instruments Ltd (Antrim, U.K.). Cayman’s COX fluorescent inhibitor screening assay kit was 
obtained from Cambridge Bioscience Ltd (Cambridge, U.K.). 
 
Methods 
Synthesis, Purification and Identification 
NSAID-peptide hybrids (IbuFFKK, IndFFKK and NpxFFKK) were synthesized as per 
standard Fmoc-based solid-phase peptide methods using a nitrogen bubbler apparatus [18]. 
Wang resin preloaded with Fmoc-Lys(Boc) was utilized to produce carboxylic acid 
terminated peptides, upon cleavage with 95% v/v trifluoracetic acid, 2.5% v/v 
triisopropylsilane and 2.5% v/v thioanisole for 3 hours at room temperature. The peptide 
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amine terminus was conjugated to the corresponding carboxylic acid of the NSAID before 
cleavage. Standard HBTU coupling was performed in dimethylformamide (DMF) with 4-fold 
molar excess of DIEA and 3-fold excess of Fmoc-protected amino acid or NSAID used for 
coupling for 3 hours at room temperature. Precipitation was achieved using cold diethyl ether 
(-20 °C). Crude product was dissolved in ethyl acetate and subjected to a series of washes 
with 1 mM HCl (3 x 50 ml) and water (3 x 50 ml and dried over anhydrous magnesium 
sulfate (MgSO4). NSAID-peptide identities were confirmed using 
1H NMR analysis (Varian 
Unity Inova 400 spectrometer, Varian systems, Palo Alto, California, U.S.A.) in d6-DMSO 
and electrospray mass spectroscopy (Thermo Finnigan LCQ Deca ion trap, Thermo Fisher 
Scientific, Waltham, Massachusetts, U.S.A.). NSAID-peptide purity was determined by 
reverse-phase-HPLC (Agilent 1260 series, Agilent Technologies Ltd, Cork, Ireland), using a 
Gemini C18 column (250 mm x 4.6 mm) with a flow rate of 1.5 mL/min and gradient of 2-
60% acetonitrile (30 minutes) in 0.05% TFA-water. All NSAID-peptides were found to have 
purity greater than 95%. 
 
Self-Assembling pH-Triggered Gelation 
NSAID-peptide hydrogels prepared by a process of pH-triggered induction [18]. The method 
of gelation followed the sequence of steps outlined for of 2% w/v NSAID-peptide 
formulations in Table 1. A stock solution was prepared by suspending each NSAID-peptide in 
deionized water. Complete dissolution was achieved at pH 9 via titration with 1 M NaOH due 
to deprotonation of the terminal carboxylic acid moiety. Changes in pH were monitored using 
Whatman pH paper. Protonation of the terminal carboxylate ion, by titration with 0.5 M HCl 
to pH 7, enabled formation of homogeneous hydrogels at concentrations above the minimum 
gelation concentration (% w/v) for each molecule. Minimum gelation concentration (% w/v) 
was defined as the lowest concentration of NSAID-peptide that formed a self-supporting 
hydrogel, observed via a gel inversion assay after 24 hours development [30]. Gels and 
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solutions were differentiated based on flow characteristics with gels remaining suspended and 
solutions demonstrating flow. 
 
Cryo-Scanning Electron and Transmission Electron Microscopy 
NSAID-peptides were prepared via pH induction as described and analyzed for 3D 
morphology using a Hitachi Analytical Benchtop SEM TM3030 (Hitachi High-Technologies 
Europe, Berkshire, U.K.) with Deben Cool Stage (Deben, Suffolk, U.K.). Cryo-SEM samples 
were freeze-dried by vacuum lyophilization at 2 °C. Images were obtained at -10 °C, using an 
accelerating voltage of 15 kV and a range of magnifications (15-30 000x) [31]. TEM was 
performed using a FEI Morgagni 268 transmission electron microscope (FEI electronics, 
Burlington, Massachusetts, U.S.A.). A negative staining technique was employed [31]. TEM 
samples were placed on 400 mesh copper grids, glow discharged and coated with a carbon 
film (35nm), rinsed thrice with double distilled water, then stained trice with a 2% w/v 
solution of uranyl acetate. Excess stain was removed by blotting with filter paper. The grids 
were left to air dry prior to examination of the 3D architecture of the NSAID-peptide samples. 
 
Fourier Transform Infra-Red Spectroscopy 
FTIR spectra were obtained at a resolution of 2 cm-1 and over wavelengths 4000-400 cm-1 
(128 scans) using a Jasco 4000 series FTIR spectrometer (Jasco Inc. Tokyo, Japan). Samples 
were prepared as described above but using deuterated solvents (D2O, DCl, NaOD). 
Hydrogels were sandwiched between two calcium fluoride discs (0.05 mm spacer). A D2O, 
DCl, NaOD mixture, prepared to the same concentrations as NSAID-peptide containing 
samples, was used as a background and subtracted from all spectra.   
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Oscillatory Rheology   
Dynamic rheological measurements were performed using an Anton Paar Physica MCR301 
rheometer. A cup and vane measuring system was used to perform frequency sweeps. For 
frequency 2 mL of the gels were prepared in 7 mL Sterilin vials as described previously [30]. 
All experiments were performed at 25 °C from 1-100 rad s-1 at a strain of 0.0003 %. 
 
Bacterial Susceptibility Assay 
The ability of NSAID-peptides to reduce bacterial viability were tested using a colony 
counting method previously outlined by Mateescu and Jiang [32,33]. S. epidermidis (ATCC 
25984), S. aureus (ATCC 6584), P. aeruginosa (PAO1) and E. coli (ATCC 11303) were 
subcultured for 24 hours at 37 °C in Müller Hinton broth (MHB), optically adjusted to an 
optical density reading of 0.3 at 550 nm (1 × 108 colony forming units per milliter (CFU/mL)) 
in phosphate buffered saline (PBS) and further diluted in MHB (equivalent to 2 × 106 
CFU/mL) prior to plating 100 μL into each well of a microtiter plate containing 100 μL of 
self-assembled NSAID-peptide (2-0.5% w/v) prepared as described above. Control wells 
included bacteria treated with PBS, as the negative control (100% survival) and 2% w/v 
HPMC as an inert hydrogel to study the effect of gelation on bacterial viability. Inoculated 
microtiter plates were incubated for 24 hours in a Gallenkamp gyrorotary incubator (37 °C) 
and 20 μL samples were taken from each well, serially diluted in PBS and transferred onto 
Müller Hinton agar plates for colony counting via the Miles and Misra method. Results were 
displayed as the mean (Log10 CFU/mL) of four replicates. 
 
Cyclooxygenase Enzyme Inhibition Assay 
The anti-inflammatory activity of the NSAID-peptides (1- 2000 µM) were determined against 
both COX-1 and COX-2 enzymes using a COX Fluorescent Inhibitor Screening Assay Kit. 
Reagents used were supplied and prepared according to the kit protocol. Potassium hydroxide 
  
10 
 
(KOH), DMSO, COX-1 (SC-560) and COX-2 (DuP-697) inhibitors were supplied ready for 
use. Assay buffer (x10) (final formulation: 100 mM Tris-HCl, pH 8.0), heme, arachadonic 
acid (final concentration: 2 mM) were prepared as per kit instructions. The test plates (one 
plate per COX enzyme) were set up according to the kit protocol with triplicates for each 
NSAID-peptide concentration. The inhibitor/sample was incubated with the enzyme for 5 
minutes at room temperature. 10 μL of 10-acetyl-3, 7-dihydroxyphenoxazine (ADHP) was 
added followed by 10 μL of arachidonic acid (reaction initiator). The plates were incubated 
for 2 minutes at room temperature and then read at an excitation wavelength of 530 nm and an 
emission wavelength of 585 nm using a FLUOstar Omega Fluorometer (BMG Labtech, 
Ortenberg, Germany) and Gen5 data analysis software (BioTek, Swindon, U.K.). IC50 
(concentration needed to inhibit COX activity by half) values were interpreted from activity 
curves (Log10 inhibitor vs normalized response) using GraphPad Prism 6 (GraphPad Software 
Inc, California, USA). The percentage inhibition of the COX enzymes was calculated by 
measurement of respective emission wavelengths (585nm) and using Equation 1. 
 
 
100
/
0
0 x
activityCOX
activitypeptideNSAIDactivityCOX
Inhibition
inhibitorno
inhibitorno 

 
(1) 
 
In each case, the background fluorescence was subtracted from each fluorescence value 
obtained. The percentage inhibition of the test inhibitors SC-560 and DuP-697 enabled a 
direct comparison to be made between the NSAID-peptide activity and that of a known 
inhibitor. NSAID only wells ((±)-ibuprofen, indomethacin, (S)-(+)-naproxen: 1-50 µM) were 
tested to determine whether or not conjugation of the NSAID to the peptide altered anti-
inflammatory activity/selectivity. All compounds were assayed in triplicate. 
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Hemolysis Assay 
The ability of NSAID-peptides to induce hemogolobin release from fresh equine erythrocytes 
was tested using a method previously outlined by our group [34]. 100 μL of equine 
erythrocytes were treated with 100 μL of NSAID-peptides for 1 hour at 37 °C. Control wells 
included 0.1% v/v Triton X-100 (100% hemolysis, positive control) and PBS (0% hemolysis, 
negative control). Following incubation the erythrocytes were centrifuged at 1000 g and 
aliquots of the supernatant used to determine hemoglobin released in a fresh 96-well 
microtiter plate read at 405 nm using a Tecan Sunrise plate reader (Tecan UK Ltd, Reading, 
U.K.) and Equation 2 below. Results are reported as the mean of six replicates. 
 
100
1.0
Peptide
4050
0405
405405
0
0 x
PBSAbsTritonXAbs
PBSAbsAbs
Hemolysis
mnm
nmnm



  
(2) 
 
Cell Viability Assay 
Cell cytotoxicity was assessed using murine fibroblast subcutaneous connective tissue NCTC 
clone 929 (ATCC CCL 1). Cells were cultured in Minimum Essential Medium (MEM) 
containing phenol red with Earle’s Salts and L-glutamine, supplemented with 10% horse 
serum and 1% penicillin and streptomycin (Invitrogen, Paisley, U.K.). Cells were grown at 
37 °C and 5% CO2 and subcultured at 80-90% confluency. Subculturing involved removal of 
spent media, washing with sterile PBS and detachment of cell monolayers with 0.05% trypsin/ 
0.53 mM EDTA.4Na solution (Invitrogen, Paisley, U.K.). Cells were cultured until at least 
third passage and inoculated at 1 x 104 cells per well in 96-well microtiter plate and incubated 
for 24 hours. The media was then removed and the cells exposed to 100 μL of a range of 
NSAID-peptide samples for 24 hours. Control wells included PBS (100% viability, negative 
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control) and 70% ethanol treated cells (100% kill, positive control). Following exposure to 
NSAID-peptides, cell viability was assessed using a 10% v/v solution of alamarBlue® diluted 
in supplemented MEM and allowed to develop for 10 hours. Absorption was measured at 570 
nm using a Tecan Sunrise plate reader. Cell viability was calculated using Equation 3 below 
and reported as the mean of six replicates. 










 100
70
Peptide
100
5700
0570
570570
0
0 x
PBSAbsEthanolAbs
PBSAbsAbs
viability
nmnm
nmnm
  
(3) 
 
Statistical Analysis 
Statistical analyses were performed using Microsoft Excel 2013 and GraphPad Prism 6. 
Standard deviations were obtained at each concentration of NSAID-peptide tested based on 
six replicates for quantitative bacterial viability assays and mean values obtained. For cell 
cytotoxicity assays standard deviations and mean values were also obtained from six 
replicates at each concentration. Statistical analyses were employed using a Kruskal-Wallis 
test, with a Dunn’s multiple comparisons test used to identify individual differences between 
the reduction in bacterial viability for each NSAID-peptide hydrogel relative to the negative 
PBS control. A Kruskal-Wallis test, followed by a Dunn’s multiple comparisons test, was also 
utilized for statistical analysis of tissue culture cytotoxicity data by comparison of percentage 
viability for the NSAID-peptides employed to the PBS negative control (100% viability). 
Hemolysis data was compared by the same statistical method with percentage hemolysis 
compared to the PBS, negative, non-hemolytic, control (0% hemolysis). Non-parametric 
Kruskal-Wallis tests were employed rather than parametric Analysis of Variance (ANOVA) 
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as data was shown to be non-normally distributed using the Kolmogorov and Smirnov method.  
In all cases a probability of p < 0.05 denoted significance. 
 
Results and Discussion 
Gel Inversion Assay 
A variety of methods exist to successfully induce peptide hydrogelation including pH, thermal 
(heat-cool) and enzymatic means. In order to ensure the conditions that mediate hydrogelation 
were replicated as closely as possible we decided to utilize a pH-triggered approach, to a final 
physiological pH of 7.4, at room temperature and using L-amino acid isomers. 
Diastereoisomers of NSAID peptides have previously demonstrated different behavior in 
relation to self-assembly and hydrogelation [25]. All NSAID-peptides formed clear solutions 
at pH 9 and above. Hydrogelation is driven by subsequent titration of acid, highlighting the 
role of the terminal carboxylic acid moiety in self-assembly [18].  
 
To enable hydrogelation a critical balance is required between molecular hydrophilicity and 
hydrophobicity with the surrounding medium, primarily water, providing excellent capacity 
for hydrogen bonding [35,36]. NpxFFKK demonstrated the greatest capacity to form stable 
hydrogels possessing a critical gelation concentration of 0.4% w/v (Table 2, Figure 2c and S7). 
IbuFFKK was unable to form hydrogels in standard deionized water (H2O) instead forming an 
opaque, white precipitate (Figure S4). Interestingly IbuFFKK formed a transparent soft gel at 
2% w/v using deuterated water (D2O) (Figure 2a and S5). This phenomenon may be due to 
increased hydrogen bond strength between deuterated hydrogen and electron donors (amines, 
carbonyl and carboxylic acid groups) present within the NSAID-peptide primary structure 
[37,38]. The number of hydrogen bonds per molecule of water is also higher for deuterated 
water compared to standard water [38]. As hydrogel formation is a delicate balance between 
solubilization and precipitation the use of deuterated water may favor increased hydrogen 
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bond formation and improved solubilization for IbuFFKK resulting in formation of a clear 
hydrogel at 2% w/v. IndFFKK was able to form a self-supporting supramolecular hydrogel at 
1.5% w/v (Figure S6) becoming an increasingly white and opaque hydrogel as the 
concentration increased to 2% w/v (Figure 2b). 
 
Microscopy 
Transmission electron microscopy (TEM) and cryogenic scanning electron microscopy (cryo-
SEM) were utilized to examine the nanoscale architecture of the molecular assemblies. 
NpxFFKK hydrogels were found to be composed of nanofibers that entangled to form an 
entangled network (Figure 3c and S8c and S10c). Naproxen has previously demonstrated 
ability to self-assemble into supramolecular hydrogels with nanofibrous architecture when 
attached to a variety of peptidomimetic molecules including peptide amphiphiles and β-
peptides [21,39].  By contrast 2% w/v IbuFFKK forms less uniform, non-fibrous structures in 
the presence of deuterated water (Figure 3a and S8a and S10a). Interactions between these 
nanoparticles and the surrounding solvent are sufficient to form a self-supporting 
supramolecular hydrogel as defined by the vial inversion assay [30]. However rheological 
analysis, detailed below, confirms that the resulting material more closely resemble a viscous 
liquid with surfactant-like properties. Cryo-SEM images for 2% w/v IbuFFKK in standard 
deionized water show the presence of a non-uniform fibers (Figure S9a) and particles (Figure 
S9b) that result in formation of a white precipitate. IndFFKK formed short nanotape-like 
structures (Figure 3b and S8b and S10b) where hydrophobic segments are packed tightly 
away from the aqueous interface. These appear less uniform, forming areas of dense pockets, 
compared to the nanofibrous architecture of NpxFFKK. These networks of, varying 
morphologies, are responsible for the immobilization of surrounding solvent molecules 
resulting in gel formation [21]. The structural morphologies correlate well to the oscillatory 
rheological profiles, most notably the storage moduli, as discussed further below.  
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However, the molecular-level understanding of the exact mechanism of peptide gelation 
kinetics remains unclear despite extensive research and warrants further investigation within 
the field [40]. It should also be noted that analysis of TEM images of gels, such as 
morphology of fibers, may not accurately represent the gel network and so should be done 
with caution. TEM images are of dried gels, whereas tests such as rheology are carried out on 
wet gels. Therefore, the structures observed by SEM could be due to drying effects [41,42].  
 
Fourier Transform Infrared Spectroscopy 
The secondary structures of NSAID-peptide nanostructures were determined by Fourier 
Transform Infrared (FTIR) spectroscopy. All FTIR studies were conducted in deuterated 
solvents, acknowledging the difficulty encountered using standard water due to strong 
absorbance within the amide I region (1700-1600 cm-1) [21]. The amide I band is generated 
through stretching of the C=O bond and its participation in hydrogen bonding provides an 
insight into peptide secondary structures. All NSAID-peptides were studied at or above 
critical gelation concentrations (2% w/v). NpxFFKK demonstrated the most predominant β-
sheet secondary structure characterized by a strong reduction in transmittance at 1630 cm-1 
(Figure S11) [43]. This trough is less pronounced for IndFFKK and particularly IbuFFKK 
owing to less uniform nanoparticle and nanotape structures respectively. However, they both 
possess a shoulder-like reduction in transmittance at 1679 cm-1 possibly linked to the presence 
of antiparallel β-sheets (Figure S11). Increased concentration of NpxFFKK, from 0.5 to 2.0% 
w/v, correlated to a respective reduction in transmittance at 1630 and 1679 cm-1 owing to a 
greater presence of β-sheet secondary structures and more rigid hydrogels at 2% w/v 
NpxFFKK (Figure S12). However, interpreting this data for short dipeptide molecules is often 
difficult as has been seen with other ultrashort peptide hydrogels. 
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Oscillatory Rheology 
Oscillatory rheology was utilized to study the viscoelastic properties of 2% w/v self-
assembled NSAID-peptide hydrogels (Figure 4). The frequency dependence of their storage 
(Gʹ) and loss moduli (Gʺ) were measured using a dynamic frequency sweep, varying the 
oscillation frequency (1-100 rad s−1) at a constant oscillation amplitude (0.0003%) and 
temperature (25 °C). 
 
NpxFFKK exhibits viscoelastic properties of a solid-like material as observed by the maximal 
storage modulus (Gʹ: ~398 Pa) being ten times larger than the maximal loss modulus (Gʺ: 
~39.8 Pa). They are independent of frequency and demonstrate good tolerance to external 
shear force. NpxFFKK has the highest mean storage modulus and greatest gel strength of the 
NSAID-peptides (Gʹ: ~398). Its Gʹ and Gʺ are comparable to that of the widely reported 
FmocFF hydrogels [44]. A larger conjugate system, conferred by the presence of naproxen in 
NpxFFKK (Figure 1c), enables stronger π- π and van der Waals’ intermolecular interactions 
between NpxFFKK molecules and allows longer fibers and more entangled arrangement of 
nanofibers as observed via microscopy (Figure 3c). Similarly IndFFKK is capable of forming 
a stable hydrogel at 2% w/v possessing a mean Gʹ of 25.1 Pa and a mean Gʺ of 6.6 Pa. 
Reduced Gʹ and Gʺ in comparison to NpxFFKK is explained by formation of shorter nanotape 
architectures rather than longer nanofiber structures observed in NpxFFKK gels (Figure 3b 
and S8b and S10b). Despite forming what appears to be a self-supporting hydrogel upon 
inversion at a concentration of 2% w/v in deuterated water (Figure 2a), rheology confirms 
IbuFFKK does not form a hydrogel with significant mechanical rigidity. A high dependence 
on frequency shows that it is behaving as a liquid rather than a gel, as gels show no 
dependence on frequency. This is due to reduced aromatic-aromatic (π- π) interactions 
provided by the terminal isopropyl-substituted phenyl group of IbuFFKK (Figure 1a) that are 
only sufficient to allow formation of non-uniform nanoparticle structures. This result is 
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similar to that observed previously by the Xu group where IbuFF demonstrated a low Gʹ value 
of only 13 Pa [25].  
 
Bacterial Susceptibility 
The antibacterial activity of NSAID-peptides was tested using a viable count assay after 24 
hour exposure to varying concentrations of NSAID-peptides. Clinically relevant bacterial 
strains, implicated in a variety of antibiotic resistant nosocomial infections (biomaterial and 
wounds), were selected, namely: methicillin resistant S. epidermidis (ATCC 25984), S. aureus 
(ATCC 6584), P. aeruginosa (PAO1) and E. coli (ATCC 11303). All NSAID-peptides 
demonstrated broad-spectrum antibacterial activity (Gram-positive and Gram-negative) 
(Figure 5 and 6 and S13 and S14). The mechanism of action of our NSAID-peptides is likely 
to follow the key parameters of antimicrobial peptide activity, namely hydrophobic bulk and 
cationic charge enabling interaction with bacterial membranes [13]. The addition of two units 
of cationic charge, in this case lysine, to an ultrashort (less than seven amino acid units) 
peptidomimetic sequence is sufficient to confer antimicrobial activity [34]. As previously 
demonstrated by our group, the ε-amino group of lysine has the ability to interact with 
negatively charged bacterial membranes and their anionic hydroxylated phospholipids 
resulting in detergent-like effects, cell lysis and death [18]. 
 
At least a three Log10 CFU/mL (99.9%) reduction in viable bacteria, commonly employed as a 
threshold for bactericidal efficacy, was observed for each NSAID-peptide at concentrations of 
0.5% w/v and above [45]. Statistical analysis, however, shows NpxFFKK to be the only 
NSAID-peptide that is significantly bactericidal against all four isolates with improved 
activity correlating to increased concentration. For example, significant bacterial kill was 
achieved at concentrations of 1.5% w/v and above for Gram-negative P. aeruginosa and E. 
coli; 1.0% and above for Gram-positive S. epidermidis and 0.5% w/v and above for S. aureus. 
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A reduction greater than 5.5 Log10 CFU/mL was obtained for 2% w/v NpxFFKK against S. 
epidermidis and S. aureus. The improved antimicrobial efficacy of NpxFFKK may be related 
to its ability to form a viscoelastic hydrogel of uniform nanofibrous architecture. Recent 
studies have suggested that that molecular folding, structural conformation, assembly state 
and bulk mechanical properties are important considerations for the rational design of 
antimicrobial selective hydrogels [17,46,47]. We propose our NpxFFKK hydrogel acts 
similarly to the dimethyldecylammonium chitosan-graft-poly(ethylene glycol) methacrylate 
(DMDC-Q-g-EM) ‘anion sponge’ developed by the Chan-Park group [48]. Based on this 
theory, the nanoporous architecture of cationic NpxFFKK allows increased interactions, 
termed ‘suctioning,’ with anionic constituents of the bacterial membrane. Therefore the 
hydrogel acts as a molecular sponge resulting in bacterial membrane disruption and cell death.  
 
The inclusion of cationic charge density within the hydrogel matrix is a key parameter for 
selective antimicrobial activity as demonstrated by the range of β-hairpin hydrogels (MAX, 
PEP6R and MARG) developed by the Schneider group [49,50,51] Hydrogelation alone is not 
sufficient to bestow antimicrobial activity, for example by restricting the diffusion of 
chemical messengers and nutrients. This is confirmed by the observed lack of efficacy of non-
ionic 2% w/v hydroxypropyl methylcellulose (HPMC) against all bacterial isolates. This is an 
unsurprising observation given that bacteria commonly prefer to exist and successfully 
survive within a surface-attached, extracellular polymeric matrix granted by the biofilm 
phenotype. As the Dong group hypothesized for their multi-domain peptides, the combined 
effect of localized cationic charge on the hydrogel surface and the porous network of 
crosslinked nanofibers (Figure 3c and S8c and S10c) are likely to be responsible for the 
improved antimicrobial efficacy of NpxFFKK [32,47]. Our ultrashort peptide motif possesses 
improved antimicrobial efficacy compared to related peptide-based strategies in the literature 
at a reduced polymer size and increased ease of synthesis.   
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Chronic wounds fail to heal and are characterized by persistent inflammation due in part to 
the presence of bacterial biofilms [52]. Research by Wolcott and Rhodes also demonstrated 
that the presence of bacterial infection in chronic wounds perpetuates a destructive level of 
inflammation [53]. Treatments active against resistant bacteria allowed non-healable, chronic 
wounds to heal. They concluded that topical agents with the ability to disrupt biofilm forming 
microorganisms should be central to the treatment of chronic wounds [54]. Previous work by 
our group demonstrates the significant efficacy of the FFKK-OH peptide motif against 
biofbacterial isolates. They may have a significant clinical benefit for the treatment of chronic 
infected wounds [18]. Whilst NSAIDs have recently been demonstrated to possess 
antibacterial activity alone by specifically targeting DNA Clamp, a key bacterial protein 
involved in multiplication, its inclusion within our motif is primarily to provide potential anti-
inflammatory, analgesic and self-assembly characteristics [55]. The benefits of NSAIDs as 
antibiotic therapy in their own right have to be verified clinically. Such studies provide hope 
to extend the currently available antibiotic formulary utilizing a readily available and licensed 
group of drugs.   
 
These results may inform future strategies whereby the host immune response is controlled in 
combination with antimicrobial and antibiofilm activity. For example IDR-1018, a synthetic 
variant of the host defense peptide LL-37, has an ability to inhibit biofilm formation in 
combination with immunomodulatory effects which prevent tissue damage [56]. Although 
IDR-1018 did not display an ability to self-assemble into supramolecular structures the 
Hancock group did demonstrate antibiofilm peptides could be used to control mediators of the 
immune response, including stimulating monocyte chemoattractant protein (MCP-1) and 
inhibiting lipopolysaccharide induced interleukin-1β (IL-1β) production in peripheral blood 
mononuclear cells [57]. 
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Cyclooxygenase Enzyme Inhibition 
We performed in vitro inhibition assays for both COX-1 and COX-2 in the presence of 
varying concentrations of NSAID-peptides. Molecular modeling, utilizing the crystal structure 
of COX enzymes, has previously shown that the NSAID carboxylate end is available for 
peptide modification due to the large open space in the structure of COX [46,58]. Addition of 
the peptide sequence FFKK-OH to the NSAID motif increases respective IC50 values relative 
to NSAID only values. However, the NSAID-peptide motifs retain significant inhibitory 
activity with IC50 values within the μM range. For example, NpxFFKK exhibits IC50 values of 
204.20 μM and 73.47 μM against COX-1 and COX-2 respectively compared with naproxen 
only values of 13.26 μM (COX-1) and 8.365 μM (COX-2) (Figure S15). NSAID-peptides 
also demonstrate increased selectivity for inhibiting COX-2 compared to NSAID alone. 
Selectivity (S) values, related to the ratio of IC50 COX-1: IC50 COX-2, are highest for 
NpxFFKK (S = 2.78) compared to naproxen only (S = 0.19). This correlates to previous work 
on NSAID-peptide hydrogelators where it was proven that addition of a peptide moiety 
increased COX-2 selectivity [25,26]. Replacing L-amino acid enantiomers with their 
respective D-forms may increase inhibition of COX-2 further [46]. Selective COX-2 
inhibition is preferred clinically, especially for systemic administration of NSAIDs, due to a 
reduction in renal and gastrointestinal side effects linked to COX-1 inhibition but may also 
have potential value in the chronic wound environment [59]. Studies have shown that upon 
degradation, the pharmaceutical efficacy of NSAIDs in theory should be maintained and 
pharmacological activity exhibited until the hydrogel has completely degraded. Therefore an 
extended profile of anti-inflammatory activity should be possible [60]. 
 
COX-2 and its enzymatic product prostaglandin E2 (PGE2) demonstrate an important role in 
the early acute host response to stimuli such as wounds and are responsible for the 
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upregulation of inflammatory mediators. Separate studies in murine and rat wound models by 
Blomme and Futagmi showed a significant induction of COX-2 expression after 12 hours, 
peaking three days after injury [61,62]. However within chronic wounds, COX-2 has recently 
been associated with the unwanted development of scar tissue in the latter stages of adult 
wound repair [63,64]. Therefore NSAID-peptide conjugates with increased selectivity for 
COX-2 inhibition may be of benefit in the chronic stages of wound healing, replicating fetal 
wound healing where scarless healing is linked to a reduced inflammatory response [64]. 
Despite this there is an appreciation that wound healing is a complex pathway and the exact 
role of multiple inflammatory mediators (cytokines, macrophages, matrix metalloproteinases) 
has not yet been fully elucidated [6]. In particular, the diverse nature of the immune and 
inflammatory response to foreign medical implants favors the use of corticosteroids, rather 
than NSAIDs, due to their broad-spectrum of activity against inflammatory mediators such as 
leukotrienes [65]. NSAID-peptides may serve a greater purpose within chronic wound healing, 
providing localized pain relief, antimicrobial and anti-inflammatory activity. Removal of an 
avascular fibrous capsule that surrounds implanted medical devices may be promoted by 
inclusion of pro-angiogenic factors including vascular endothelial growth factor (VEGF). Our 
nanomaterials have the potential to act as a drug delivery platform for the design of future 
medical device coatings incorporating such factors [11]. The effect of NSAID-peptides 
nanostructures on mediators of the immune response. The overall wound healing pathway and 
foreign body response to medical implants warrants further clinical investigation. A more 
obvious therapeutic benefit for NSAID-peptides is provided via inhibition of nociception and 
pain receptors linked to COX [66]. Reduction in pain can be linked to improvement in wound 
healing and patient prognosis [67]. 
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Hemolysis and Cell Viability 
To evaluate cell biocompatibility of NSAID-peptides, they were incubated with an 
International Standard (ISO) cell line utilized for biomaterial testing (NCTC 929 murine 
fibroblast subcutaneous connective tissue). Fibroblasts are appropriate as they are one of the 
major cell types involved both in wound healing and adherence to implanted medical devices 
[11]. The results suggest that NSAID-peptide nanomaterials are biocompatible and may be 
suitable for use within a range of biomaterial and topical applications. No significant 
reduction was observed in cell viability after 24 hour exposure to varying concentrations of 
NSAID-peptides (20-500 mM) utilizing an alamarBlue® cell viability assay (Figure 7). 
Cationic NSAID-peptides demonstrate reduced toxicity against mammalian cells due to 
inherent differences in the membrane potential gradient and lipid composition of bacterial and 
mammalian cell membranes. Eukaryotic cells are composed of zwitterionic lipids (sterols, 
cholesterol, phosphatidylcholine, sphingomyelin) whereas bacterial cells are derived from 
anionic phospholipids [68]. Positively charged NSAID-peptide therefore interact 
preferentially with negatively charged bacterial cell membranes as confirmed by a hemolysis 
assay (Figure S16), commonly utilized to determine the membrane selectivity of antimicrobial 
peptides [18,32,69]. No significant hemolysis was observed upon NSAID-peptide (20-500 
mM) exposure to equine erythrocytes relative to a PBS negative control.   
 
Conclusions 
In conclusion, we have created a new class of NSAID-peptides with the ability to form 
defined nanostructures with multiple biofunctional properties (antimicrobial, anti-
inflammatory, hydrogel forming). NpxFFKK displays particular promising forming a 
viscoelastic biocompatible hydrogel with improved COX-2 selectivity and the ability to target 
antimicrobial resistant bacteria implicated in the most severe nosocomial infections. These 
hydrogel formulations may be beneficial in the treatment of chronic infected wounds, where a 
  
23 
 
heightened inflammatory response to infection leads to impaired healing. Their ultrashort, low 
molecular weight structure makes their synthesis more amenable to cost-effective upscale by 
the pharmaceutical industry compared to larger peptides and proteins. This work provides an 
example of multifunctional peptide hydrogelators that will contribute to the development of 
future biofunctional nanomaterial therapies, especially within biomaterial applications (wound 
dressings, medical implants, prostheses), thereby increasing the available treatment options to 
clinicians and patients and limiting the increasing threat of antimicrobial resistance.   
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Figure 1. Chemical structures of NSAID-peptides investigated: (a) IbuFFKK, (b) IndFFKK, 
(c) NpxFFKK. 
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Figure 2. Gel inversion assay for 2% w/v pH 7.4 (a) IbuFFKK, D2O primary vehicle, (b) 
IndFFKK, H2O primary vehicle (c) NpxFFKK, H2O primary vehicle. 
 
 
 
Figure 3. Transmission electron microscopy (TEM) images of 2% w/v (a) IbuFFKK (28,000x, 
D2O), (b) IndFFKK (18,000x, H2O), (c) NpxFFKK (28,000x, H2O). 
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Figure 4. Oscillatory frequency sweep 2% w/v NSAID-peptides. Key: black triangle: Gʹ 
IbuFFKK, white triangle: Gʺ IbuFFKK , black circle: Gʹ IndFFKK, white circle: Gʺ IndFFKK, 
black square: Gʹ NpxFFKK, white square: Gʺ NpxFFKK. 
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Figure 5. Logarithmic reduction in S. aureus (ATCC 6584) viable count (Log10 CFU/mL) 
after 24 hour incubation with varying concentrations of NSAID-peptides.  Results are 
displayed as a mean of six replicates.  Key: grey column: IbuFFKK, striped column: 
IndFFKK, white column:  NpxFFKK, dotted line: PBS control, black line: 2% w/v HPMC 
control. NS: no significant difference (P≥0.05), *: P<0.05, **: P<0.01 significant difference 
between Log10 CFU/mL of NSAID-peptide and the negative control (PBS). 
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Figure 6. Logarithmic reduction in P. aeruginosa (PAO1) viable count (Log10 CFU/mL) after 
24 hour incubation with varying concentrations of NSAID-peptides.  Results are displayed as 
a mean of six replicates.  Key: grey column: IbuFFKK, striped column: IndFFKK, white 
column:  NpxFFKK, dotted line: PBS control, black line: 2% w/v HPMC control. NS: no 
significant difference (P≥0.05), *: P<0.05, **: P<0.01 significant difference between Log10 
CFU/mL of NSAID-peptide and the negative control (PBS). 
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Figure 7. Percentage cell viability of NCTC clone 929 (ATCC CCL 1) cells after 24 hour 
exposure to varying concentrations of NSAID-peptides. Key: striped: IbuFFKK, white: 
IndFFKK, grey: NpxFFKK, ns: no significant difference (P≥0.05) between the NSAID-
peptide and the negative control (PBS). 
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Table 1. Stepwise formulation of a self-assembling pH-triggered 2% w/v NSAID-peptide 
(500 µL). 
Formulation step Constituent a)  Quantity 
1 NSAID-peptide 10mg pre-weighed 
2 Deionized H2O or D2O 200 µL (in 50 µL aliquots) 
3 1M NaOH or NaOD 50 µL (in 10 µL aliquots) 
4 Deionized H2O or D2O 200 µL (in 50 µL aliquots) 
5 0.5M HCl or DCl 20 µL (in 10 µL aliquots) 
6 Deionized H2O or D2O to 500 µL 
a) Deuterated solvents employed for FTIR purposes and IbuFFKK where relevant in text 
 
Table 2. Critical gelation concentrations (% w/v) for each NSAID-peptide. Observation via 
inversion test. 
NSAID-peptide Critical gelation concentration (% w/v) 
IbuFFKK 2 a) 
IndFFKK 1.5 
NpxFFKK 0.4 
a) Deuterated solvents employed 
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Self-assembling Ultrashort NSAID-Peptides: Multifunctional Antimicrobial and Anti-
inflammatory Nanomaterials  
 
Alice P. McCloskey, Sophie M. Gilmore, Jie Zhou, Emily R. Draper, Brendan F. Gilmore, 
Bing Xu, Garry Laverty*  
 
Ibuprofen-L-phenylalanine-L-phenylalanine-L-Lysine-L-Lysine-COOH (IbuFFKK). 1H NMR 
(400 MHz, DMSO-d6, δ): 8.21-8.02 (m, J = 4.06, 4H; NH), 7.66 (s, J = 4.13, 4H; NH2), 7.25-
6.99 (m, J = 14.26, 14H; Ar H), 4.57-4.18 (m, J = 4.40, 4H, CHNH), 3.03 (q, J = 1.08, 1H; 
CHCH3), 2.84-2.68 (m, J = 10.75, 8H; CH2Ar, 2H; CH2NH2), 2.39 (d, J = 3.23, 3H; CH3), 
1.54-1.07 (m, J = 17.54, 2H; Ar CH2CH(CH3)2 , 1H; CH2CH(CH3)2, 12H; CH2), 0.86-0.83 (m, 
J = 6.51, 6H; CH3). EIMS m/z (%): 756.46 (100) [M
+], 757.46 (46.5) [M+ +H]+, 758.46 (10.6) 
[M++2H]+; (ESI) m/z: [M + H]+ calcd for C43H60N6O6, 756.99; found, 756.46.  
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Figure S1. 1H NMR.spectra for IbuFFKK (C2D6OS, TMS standard, 400MHZ). 
 
Indomethacin-L-phenylalanine-L-phenylalanine-L-Lysine-L-Lysine-COOH (IndFFKK). 
1H NMR (400 MHz, DMSO-d6, δ): 8.21-8.16 (m, J = 2.59, 1H; NH, 1H; Ar H), 7.63-7.55 (m, 
J = 4.16, 1H; Ar H, 2H; NH), 7.22-6.62 (m, J = 17.33, 14H; Ar H, 1H; NH, 4H; NH2), 4.56-
4.16 (m, J  = 5.49, 4H; CHNH), 3.74-3.67 (m, J = 4.41, 3H; CH3, 2H; CH2CO), 3.03-2.68 (m, 
J = 14.50, 4H; CH2NH2, 4H; CH2 Ar), 2.33 (s, J = 3.02, 3H; CH3), 1.89-1.24 (m,  J = 21.08, 
12H; CH2). EIMS m/z (%): 893.39 (100) [M
+], 894.39 (51.9) [M+ − H], 895.38 (32) [M+ − 
2H], 896.39 (16.6); (ESI) m/z: [M + H]+ calcd for C49H58ClN7O8, 894.47; found, 893.39.  
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Figure S2. 1H NMR.spectra for IndFFKK (C2D6OS, TMS standard, 400MHZ). 
 
Naproxen-L-phenylalanine-L-phenylalanine-L-Lysine-L-Lysine-COOH (NpxFFKK). 
1H NMR (400 MHz, DMSO-d6, δ): 8.22-8.04 (m, J = 5.53, 3H; NH, 2H; Ar H), 7.75-7.05 (m, 
J = 21.43, 14H; Ar H, 4H; NH2), 4.50-3.71 (m, J = 6.20, 4H; CHNH, 1H; Ar CHCH3), 2.98-
2.68 (m, J = 9.97 4H; Ar CH2, 4H; CH2NH2), 2.33 (s, J = 3.10, 3H; CH3), 1.73-1.03 (m, J = 
21.71, 12H; CH2, 3H; CH3). EIMS m/z (%): 780.42 (100) [M
+], 781.42 (47.6) [M+ − H], 
782.43 (11.1) [M+ − 2H]; (ESI) m/z: [M + H]+ calcd for C44H56N6O7, 780.97; found, 780.42.  
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Figure S3. 1H NMR.spectra for NpxFFKK (C2D6OS, TMS standard, 400MHZ). 
 
 
 
Figure S4. Gel inversion assay for IbuFFKK pH 7.4, H2O primary vehicle. 
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Figure S5. Gel inversion assay for IbuFFKK pH 7.4, D2O primary vehicle. 
 
 
Figure S6. Gel inversion assay for IndFFKK pH 7.4, H2O primary vehicle. 
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Figure S7. Gel inversion assay for NpxFFKK pH 7.4, H2O primary vehicle. 
 
 
Figure S8. Cryo-SEM images of 2% w/v (a) IbuFFKK (D2O), (b) IndFFKK (H2O), (c) 
NpxFFKK (H2O). 
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Figure S9. Cryo-SEM images of 2% w/v IbuFFKK (H2O primary vehicle). 
 
 
Figure S10. TEM images of 2% w/v (8900x) (a) IbuFFKK (D2O), (b) IndFFKK (H2O), 
(c)NpxFFKK (H2O). 
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Figure S11. FTIR spectra displaying amide band of 2% w/v NSAID-peptides in deuterated 
solvents. Key: dotted line: IbuFFKK, dashed line: IndFFKK , full line: NpxFFKK. 
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Figure S12. FTIR spectra displaying amide band of 0.5-2% w/v NpxFFKK peptide. Key: 
dotted line: 0.5% w/v, dashed line: 1.5% w/v, full line: 2% w/v. 
 
 
 
 
 
 
Figure S13. Logarithmic reduction in S. epidermidis (ATCC 35984) viable count (Log10 
CFU/mL) after 24 hour incubation with varying concentrations of NSAID-peptides. Results 
are displayed as a mean of six replicates.  Key: grey column: IbuFFKK, striped column: 
IndFFKK, white column: NpxFFKK, dotted line: PBS control, black line: 2% w/v HPMC 
control. NS: no significant difference (P≥0.05), *: P<0.05, **: P<0.01 significant difference 
between Log10 CFU/mL of NSAID-peptide and the negative control (PBS). 
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Figure S14. Logarithmic reduction in E. coli (ATCC 11303) viable count (Log10 CFU/mL) 
after 24 hour incubation with varying concentrations of NSAID-peptides. Results are 
displayed as a mean of six replicates. Key: grey column: IbuFFKK, striped column: IndFFKK, 
white column:  NpxFFKK, dotted line: PBS control, black line: 2% w/v HPMC control. NS: 
no significant difference (P≥0.05), *: P<0.05, **: P<0.01 significant difference between Log10 
CFU/mL of NSAID-peptide and the negative control (PBS). 
 
 
 
  
47 
 
 
Figure S15. IC50 values of NSAID-peptide and NSAIDs only molecules corresponding to 
inhibition of COX-1 (black column) and COX-2 (white column) enzymes. Selectivity (S) is 
defined as the ratio of the IC50 values relative to COX-1: COX-2.  
 
 
 
Figure S16. Percentage hemolysis of equine erythrocytes after 1 hour exposure to varying 
concentrations of NSAID-peptides. Key: striped: IbuFFKK, white: IndFFKK, grey: 
NpxFFKK, NS: no significant difference (P≥0.05) between the NSAID-peptide and the 
negative control (PBS). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
